Processa Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PCSA research report →
About the company
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment.
- CEO
- George K. Ng
- IPO
- 2014
- Employees
- 10
- HQ
- Hanover, MD, US
Price Chart
- Market Cap
- $4.89M
- P/E
- -0.20
- P/S
- 0.00
- P/B
- 2.23
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -281.30%
- ROIC
- -569.60%
- Revenue
- $0 · 0.00%
- Net Income
- $-13,563,834 · -14.46%
- EPS
- $-10.36 · 89.29%
- Op Income
- $-13,988,505
- FCF YoY
- -1.22%
- 52W High
- $14.25
- 52W Low
- $1.76
- 50D MA
- $2.49
- 200D MA
- $4.17
- Beta
- 0.99
- Avg Volume
- 67.09K
Get TickerSpark's AI analysis on PCSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Guy Wendy | buy | 2,436 |
| Jun 30, 26 | Lin Patrick | buy | 2,106 |
| Jul 1, 26 | Ng George K | buy | 3,057 |
| Jun 30, 26 | SKIBSTED RUSSELL | buy | 3,277 |
| Jun 30, 26 | Young David | buy | 2,531 |
| Jun 26, 26 | Yorke Justin W | other | 203 |
| Jun 26, 26 | Yorke Justin W | other | 203 |
| Jun 26, 26 | Pannu Geraldine | other | 203 |
| Jun 26, 26 | Pannu Geraldine | other | 203 |
| Jun 26, 26 | Neal James R | other | 203 |
Our PCSA coverage
Recent articles, reports, and earnings notes.
No research on PCSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PCSA report →Similar companies
Peers in the same neighborhood.